Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: Mixed treatment comparison using placebo as common comparator

Clinical Rheumatology

Volumn 31, Issue 1, 2012, Pages 133-137

  Migliore, Alberto ^a   Bizzi, Emanuele ^a   Broccoli, Serena ^b   Laganà, Bruno ^c  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b Srl   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adalimumab; Efficacy; Etanercept; Infliximab; Psoriatic arthritis; TNF blockers

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

AMERICAN COLLEGE OF RHEUMATOLOGY 20 RESPONSE; ANALYTIC METHOD; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HUMAN; MIXED TREATMENT COMPARISON; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84856746828     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1790-6     Document Type: Article

References (22)

1. JP Jansen B Crawford G Bergman, et al. 2008 Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons Value Health 11 956 964 18489499 10.1111/j.1524-4733.2008.00347.x
2. AE Ades M Sculpher A Sutton, et al. 2006 Bayesian methods for evidence synthesis in cost-effectiveness analysis PharmacoEconomics 24 1 1 19 16445299 10.2165/00019053-200624010-00001 1:STN:280:DC%2BD28%2Fmt1GksQ%3D%3D (Pubitemid 43197227)
3. Ades AE, Welton N, Lu G (2007) Introduction to mixed treatment comparisons. University of Bristol, Bristol, UK. https://www.bris.ac.uk/cobm/ docs/intro%20to%20mtc.doc
4. D Caldwell A Ades J Higgins 2005 Simultaneous comparison of multiple treatments: combining direct and indirect evidence Br Med J 331 7521 897 900 10.1136/bmj.331.7521.897 (Pubitemid 41502718)
5. G Lu AE Ades 2004 Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 20 3105 3124 15449338 10.1002/sim.1875 1:STN:280:DC%2BD2crhvFCqug%3D%3D (Pubitemid 39334902)
6. RM Nixon N Bansback A Brennan 2007 Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis Stat Med 26 6 1237 1254 16900557 10.1002/sim.2624 1:STN:280:DC%2BD2s7gs1Snsw%3D%3D (Pubitemid 46380839)
7. GJ Bergman MC Hochberg M Boers N Wintfeld A Kielhorn JP Jansen 2010 Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs Semin Arthritis Rheum 39 6 425 441 20223500 10.1016/j.semarthrit.2009.12. 002 1:CAS:528:DC%2BC3cXmsVaqtb4%3D
8. MC Genovese PJ Mease GT Thomson AJ Kivitz RJ Perdok MA Weinberg J Medich EH Sasso 2007 Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy J Rheumatol 34 5 1040 1050 17444593 1:CAS:528:DC%2BD2sXmtV2rtLY%3D (Pubitemid 46774851)
9. CE Antoni A Kavanaugh B Kirkham Z Tutuncu GR Burmester U Schneider DE Furst J Molitor E Keystone D Gladman B Manger S Wassenberg R Weier DJ Wallace MH Weisman JR Kalden J Smolen 2005 Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Arthritis Rheum 52 4 1227 1236 15818699 10.1002/art.20967 1:CAS:528: DC%2BD2MXktFCktbw%3D Erratum in: Arthritis Rheum 52 (9):2951 (Pubitemid 40530131)
10. PJ Mease AJ Kivitz FX Burch EL Siegel SB Cohen P Ory D Salonen J Rubenstein JT Sharp W Tsuji 2004 Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 7 2264 2272 15248226 10.1002/art.20335 1:CAS:528:DC%2BD2cXmsVansbc%3D (Pubitemid 38924405)
11. PJ Mease DD Gladman CT Ritchlin EM Ruderman SD Steinfeld EH Choy JT Sharp PA Ory RJ Perdok MA Weinberg 2005 Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 10 3279 3289 16200601 10.1002/art.21306 1:CAS:528:DC%2BD2MXhtF2msrjP (Pubitemid 41447111)
12. DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith LM Katz R Lightfoot Jr H Pauls V strand, et al. 1995 American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 6 727 735 7779114 10.1002/art.1780380602 1:STN:280:DyaK2M3pvVSmtA%3D%3D
13. NJ Cooper AJ Sutton G Lu K Khunti 2006 Mixed comparison of stroke prevention treatments in individuals with non rheumatic atrial fibrillation Arch Intern Med 166 1269 1275 16801509 10.1001/archinte.166.12.1269 (Pubitemid 43967578)
14. A Cipriani TA Furukawa G Salanti JR Geddes JPT Higgins R Churchill N Watanabe A Nakagawa IM Omori H McGuire M Tansella C Barbui 2009 Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 746 758 19185342 10.1016/S0140-6736(09)60046-5 1:CAS:528:DC%2BD1MXisVOrtr8%3D
15. N Welton D Caldwell E Adamopoulous K Vedhara 2009 Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease Am J Epidemiol 169 1158 1165 19258485 10.1093/aje/kwp014
16. JP Jansen GJ Bergman J Huels M Olson 2009 Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies Curr Med Res Opin 25 8 1861 1868 19530978 10.1185/03007990903035281 1:CAS:528:DC%2BD1MXoslals7s%3D
17. AA Saad DP Symmons PR Noyce DM Ashcroft 2008 Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trials J Rheumatol 35 5 883 890 18381787 1:CAS:528:DC%2BD1cXntVOmurc%3D (Pubitemid 351747132)
18. A Wiens R Venson CJ Correr MF Otuki R Pontarolo 2010 Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis Pharmacotherapy 30 4 339 353 20334454 10.1592/phco.30.4.339 1:CAS:528:DC%2BC3cXlsVWgtbw%3D
19. AA Saad DM Ashcroft KD Watson KL Hyrich PR Noyce DP Symmons 2009 Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register Arthritis Res Ther 11 2 R52 19356232 10.1186/ar2670
20. LE Kristensen A Gulfe T Saxne P Geborek 2008 Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register Ann Rheum Dis 67 364 369 17644547 10.1136/ard.2007.073544 1:CAS:528:DC%2BD1cXjs1ejs7s%3D (Pubitemid 351281272)
21. JJ Gomez-Reino L Carmona 2006 Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 8 R29 16507128 10.1186/ar1881
22. RE Kalb J Gurske 2005 Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo J Am Acad Dermatol 53 4 616 622 16198781 10.1016/j.jaad.2005.05.033 (Pubitemid 41399928)